Balda AG has acquired C. Brewer Company
Balda AG (Balda) has acquired C. Brewer Company in Anaheim, California.
The C. Brewer Company, a family-owned business, specializes in precision injection-molded plastics and associated molds, in particular for customers from the medical and optical industries as well as from the automotive and electronics sectors.
Germany-based Balda develops and manufactures high quality plastic systems for medical appliances as well as complete electronic products for communication and entertainment. The Balda Medical segment in Bad Oeynhausen develops and produces plastic solutions for the medical technology, pharmaceutical and diagnosis markets.
This acquisition is part of Balda’s buy-and-build strategy for its medical segment. Through this acquisition, Balda extends its presence in the strategically important US market and particularly strengthens its medical business.
Oaklins' team in Germany advised Balda on this acquisition.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more